Advances in the drug management of basal cell carcinoma. (24th March 2022)

• Record Type: Journal Article
• Authors: Ramelyte, Egle; Restivo, Gaetana; Mannino, Maria; Levesque, Mitchell P; Dummer, Reinhard
• Is Part Of: Expert opinion on pharmacotherapy. Volume 23:Number 5(2022)
• Page Start: 573
• Page End: 582
• Publication Date: 2022-03-24
• Subjects: Basal cell carcinoma -- hedgehog pathway inhibitors -- skin cancer -- NMSC; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2032646
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Basal cell carcinoma (BCC) is the most common skin cancer in humans. Recently, BCCs were suggested to be classified into 'easy to treat' and 'difficult to treat, ' and different therapeutic options are suggested for their management. Areas covered: In this review, the authors discuss treatment options that are approved, recommended for, or are still in development for treatment of BCC. The review covers approved local therapies, such as imiquimod and 5-fluorouracil, and systemic therapies, such as hedgehog inhibitors. New medical agents, investigated in clinical trials, are reviewed. These include: targeted therapies, such as GLI antagonists or anti-VEGFR agents, immunotherapies, such as checkpoint inhibitors, recombinant cytokines or silencing RNA, as well as intralesional virotherapies with modified adeno- or herpes viruses. Expert opinion: The progress made in recent years has improved the management of patients with advanced BCC; however, neither tumor targeting nor immune system engaging agents provide a cure. New treatment approaches directed not only to known targets but also the tumor microenvironment are in development and are anticipated to improve the management of difficult to treat BCC.